Publicaciones en colaboración con investigadores/as de Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer (22)

2019

  1. Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma

    Biology of Blood and Marrow Transplantation, Vol. 25, Núm. 9, pp. 1703-1712

2018

  1. Aggressive primary cutaneous CD30+ lymphoproliferative disorder in an organ transplant recipient in sustained complete remission with brentuximab vedotin

    International Journal of Dermatology

  2. Diagnosis, treatment, and response assessment in solitary plasmacytoma: Updated recommendations from a European Expert Panel

    Journal of Hematology and Oncology, Vol. 11, Núm. 1

2017

  1. Amiloride, an old diuretic drug, is a potential therapeutic agent for multiple myeloma

    Clinical Cancer Research, Vol. 23, Núm. 21, pp. 6602-6615

  2. The novel pan-PIM kinase inhibitor, PIM447, displays dual antimyeloma and bone-protective effects, and potently synergizes with current standards of care

    Clinical Cancer Research, Vol. 23, Núm. 1, pp. 225-238

2016

  1. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): A phase 3b study in refractory multiple myeloma

    Blood, Vol. 128, Núm. 4, pp. 497-503

2015

  1. Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma

    Haematologica

  2. Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: Phase Ib/II panobidara study

    Haematologica, Vol. 100, Núm. 10, pp. 1294-1300

  3. Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential

    Leukemia, Vol. 29, Núm. 5, pp. 1186-1194

2014

  1. Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma

    Blood

  2. Future agents and treatment directions in multiple myeloma

    Expert Review of Hematology, Vol. 7, Núm. 1, pp. 127-141

  3. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 Inhibition as an antimyeloma strategy

    Molecular Cancer Therapeutics, Vol. 13, Núm. 2, pp. 504-516

  4. New drugs and novel mechanisms of action in multiple myeloma in 2013: A report from the International Myeloma Working Group (IMWG)

    Leukemia, Vol. 28, Núm. 3, pp. 525-542

  5. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial

    The Lancet Oncology, Vol. 15, Núm. 11, pp. 1195-1206

  6. Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines

    PLoS ONE, Vol. 9, Núm. 3

2013

  1. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

    Leukemia, Vol. 27, Núm. 10, pp. 2056-2061

2012

  1. Multiple myeloma: Treatment evolution

    Hematology, Vol. 17, Núm. SUPPL. 1

2011

  1. Differential diagnosis of IgM MGUS and WM according to B-lymphoid infiltration by morphology and flow cytometry

    Clinical Lymphoma, Myeloma and Leukemia

  2. The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis

    Blood, Vol. 117, Núm. 13, pp. 3613-3616

2008

  1. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings

    The Lancet Oncology, Vol. 9, Núm. 12, pp. 1157-1165